Trial · NCT02926222
Regorafenib in Relapsed Glioblastoma
NCT02926222, Phase 2, Completed, Istituto Oncologico Veneto IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib in Relapsed Glioblastoma. Trials, record NCT02926222. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02926222
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib in Relapsed Glioblastoma
- NCT number
- NCT02926222
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 119 participants, actual
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- Conditions
- Glioblastoma Multiforme
- Interventions
- Regorafenib, Lomustine
- First posted
- 2016-10-06
- Last updated
- 2022-09-09
- Other registries' IDs
- eudract:2014-003722-41
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival | From the date of randomization to 18 months or to the date of death from any cause | |
| Secondary | Progression free survival | From the date of randomization to 18 months or to the date of disease progression or to the date of death, whichever occurs first | |
| Secondary | Objective response rate | Approximately 36 months | As percentage of patients achieving a complete response plus partial response |
| Secondary | Disease control rate | Approximately 36 months | As percentage of patients achieving a complete response plus partial response plus stable disease |
| Secondary | Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events) | Approximately every 4 weeks through the treatment period up to 30 days after the end of treatment | Graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE) v.4 |
| Other | Quality of life EORTC | From the date of randomization, approximately every 3 months until the date of first documented progression or date of death from any cause, or study withdrawal, whichever came first, assessed up to 30 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02926222
GET https://conductscience.org/api/trials/v1/NCT02926222/registered